| 194.11 -0.27 (-0.14%) | 04-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 244.58 | 1-year : | 258.99 |
| Resists | First : | 209.4 | Second : | 221.74 |
| Pivot price | 200.07  |
|||
| Supports | First : | 189.44 | Second : | 157.61 |
| MAs | MA(5) : | 193.26 |
MA(20) : | 203.83 |
| MA(100) : | 231.64 |
MA(250) : | 255.93 |
|
| MACD | MACD : | -7.2  |
Signal : | -6.7 |
| %K %D | K(14,3) : | 13.9 |
D(3) : | 7.7 |
| RSI | RSI(14): 31 |
|||
| 52-week | High : | 319.76 | Low : | 189.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BIIB ] has closed above bottom band by 23.6%. Bollinger Bands are 1.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 197.23 - 198.32 | 198.32 - 199.21 |
| Low: | 189.82 - 191.38 | 191.38 - 192.65 |
| Close: | 191.82 - 194.13 | 194.13 - 196.01 |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Tue, 23 Apr 2024
Biogen Inc. (NASDAQ:BIIB) Receives $295.58 Average Target Price from Analysts - MarketBeat
Tue, 23 Apr 2024
Should You Be Confident in Biogen (BIIB)? - Yahoo Finance UK
Mon, 22 Apr 2024
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Sun, 21 Apr 2024
Biogen Inc. (BIIB) Stock Jumps 5%: Will It Continue to Soar? - Yahoo Movies UK
Fri, 19 Apr 2024
What's in Store for Biogen (BIIB) This Earnings Season? - Yahoo Finance
Fri, 19 Apr 2024
Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 145 (M) |
| Shares Float | 145 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 92.9 (%) |
| Shares Short | 3,550 (K) |
| Shares Short P.Month | 2,800 (K) |
| EPS | 7.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 102.13 |
| Profit Margin | 11.8 % |
| Operating Margin | 19.3 % |
| Return on Assets (ttm) | 4.5 % |
| Return on Equity (ttm) | 8.2 % |
| Qtrly Rev. Growth | -6.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 67.69 |
| EBITDA (p.s.) | 16.37 |
| Qtrly Earnings Growth | -55 % |
| Operating Cash Flow | 1,550 (M) |
| Levered Free Cash Flow | 971 (M) |
| PE Ratio | 24.35 |
| PEG Ratio | 4.4 |
| Price to Book value | 1.9 |
| Price to Sales | 2.86 |
| Price to Cash Flow | 18.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|